S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
NYSEAMERICAN:OCX

OncoCyte Stock Forecast, Price & News

$4.76
+0.07 (+1.49 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.52
Now: $4.76
$4.91
50-Day Range
$2.12
MA: $2.38
$2.63
52-Week Range
$1.15
Now: $4.76
$4.92
Volume1.91 million shs
Average Volume1.58 million shs
Market Capitalization$320.11 million
P/E RatioN/A
Dividend YieldN/A
Beta2.23
OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network, Inc. to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.
OncoCyte logo

MarketRank

Overall MarketRank

1.67 out of 5 stars

Medical Sector

243rd out of 1,925 stocks

Diagnostic Substances Industry

4th out of 32 stocks

Analyst Opinion: 2.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OCX
CUSIPN/A
Phone(510) 775-0515
Employees33

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.59 per share

Profitability

Net Income$-22,430,000.00

Miscellaneous

Market Cap$320.11 million
Next Earnings Date3/24/2021 (Estimated)
OptionableNot Optionable
$4.76
+0.07 (+1.49 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

How has OncoCyte's stock price been impacted by COVID-19 (Coronavirus)?

OncoCyte's stock was trading at $2.14 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OCX stock has increased by 122.4% and is now trading at $4.76.
View which stocks have been most impacted by COVID-19
.

Is OncoCyte a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OncoCyte stock.
View analyst ratings for OncoCyte
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than OncoCyte?

Wall Street analysts have given OncoCyte a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OncoCyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is OncoCyte's next earnings date?

OncoCyte is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for OncoCyte
.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NYSEAMERICAN:OCX) posted its earnings results on Thursday, November, 12th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.01. The biotechnology company earned $0.56 million during the quarter, compared to the consensus estimate of $0.62 million.
View OncoCyte's earnings history
.

What price target have analysts set for OCX?

7 equities research analysts have issued 12-month price objectives for OncoCyte's shares. Their forecasts range from $4.00 to $7.75. On average, they anticipate OncoCyte's share price to reach $5.11 in the next twelve months. This suggests a possible upside of 7.3% from the stock's current price.
View analysts' price targets for OncoCyte
or view Wall Street analyst' top-rated stocks.

Are investors shorting OncoCyte?

OncoCyte saw a decline in short interest during the month of December. As of December 31st, there was short interest totaling 2,220,000 shares, a decline of 14.3% from the December 15th total of 2,590,000 shares. Based on an average trading volume of 2,090,000 shares, the short-interest ratio is presently 1.1 days.
View OncoCyte's Short Interest
.

Who are some of OncoCyte's key competitors?

What other stocks do shareholders of OncoCyte own?

Who are OncoCyte's key executives?

OncoCyte's management team includes the following people:
  • Mr. Ronald A. Andrews Jr., CEO, Pres & Director (Age 61, Pay $312.5k)
  • Mr. Mitchell S. Levine, Chief Financial Officer
  • Mr. William Annett, Advisor (Age 67, Pay $673.33k)
  • Ms. Padma Sundar, Sr. VP of Commercial
  • Dr. Douglas T. Ross M.D., Ph.D., Chief Medical Officer
  • Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 68)
  • Ms. Sara Riordan, Director of Medical Education

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by many different retail and institutional investors. Top institutional investors include Caliber Wealth Management LLC (0.05%). Company insiders that own OncoCyte stock include Albert P Parker, Alfred D Kingsley, Andrew Arno, Biotime Inc, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews and Thomas Alex Vetter.
View institutional ownership trends for OncoCyte
.

Which major investors are buying OncoCyte stock?

OCX stock was acquired by a variety of institutional investors in the last quarter, including Caliber Wealth Management LLC. Company insiders that have bought OncoCyte stock in the last two years include Albert P Parker, Andrew Arno, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews, and Thomas Alex Vetter.
View insider buying and selling activity for OncoCyte
or or view top insider-buying stocks.

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $4.76.

How big of a company is OncoCyte?

OncoCyte has a market capitalization of $320.11 million. The biotechnology company earns $-22,430,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. OncoCyte employs 33 workers across the globe.

What is OncoCyte's official website?

The official website for OncoCyte is www.oncocyte.com.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.